Lummis Asset Management LP Sells 14,731 Shares of Abbott Laboratories $ABT

Lummis Asset Management LP lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 32.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,056 shares of the healthcare product maker’s stock after selling 14,731 shares during the period. Abbott Laboratories makes up 2.7% of Lummis Asset Management LP’s portfolio, making the stock its 10th biggest position. Lummis Asset Management LP’s holdings in Abbott Laboratories were worth $4,160,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories during the third quarter worth $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories during the 3rd quarter worth approximately $31,000. Anfield Capital Management LLC boosted its position in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares during the period. Delos Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories in the second quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of several analyst reports. Argus dropped their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Royal Bank Of Canada dropped their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group reduced their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Finally, Evercore dropped their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Large end‑market tailwinds — multiple industry reports highlight strong long‑term growth for genetic testing, cancer diagnostics and personalized medicine, and name Abbott among market leaders; that supports durable demand for Abbott’s diagnostics and genomics businesses. Genetic Testing Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Sustainability, Launches, Mergers, Product Innovations, Revenue Insights
• Positive Sentiment: Analyst support and price targets remain constructive — several Buy/Overweight ratings recently reiterated and the median 6‑month target sits near $140, providing upside expectations if growth and margins recover. Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition
• Positive Sentiment: Dividend continuity — Abbott declared a $0.63 quarterly dividend (yield ~2.2%), supporting investor income expectations and signaling cash‑return discipline.
• Neutral Sentiment: Q4 results were mixed: EPS matched consensus ($1.50) but revenue (~$11.46B) trailed estimates; management provided FY‑2026 and Q1 guidance — the print shows stable profitability but moderating top‑line momentum, so near‑term reaction depends on guidance detail and margin trajectory. Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say
• Neutral Sentiment: Exact Sciences acquisition financing — Abbott announced a large bond sale (reported ~$20B) to fund the deal. The acquisition aims to deepen cancer‑screening/diagnostics exposure (strategic upside) but raises leverage and integration risk; investors are divided on whether the move is accretive. Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition
• Negative Sentiment: Legal and safety risk — a wrongful‑death lawsuit alleges defects in Abbott’s FreeStyle Libre 3 glucose monitors, claiming multiple deaths and serious injuries; this poses potential regulatory, litigation and reputational costs if claims advance. Wrongful Death Suit Tests Abbott Libre 3 And Exact Sciences Ambitions

Abbott Laboratories Trading Down 0.6%

Shares of ABT stock opened at $114.65 on Wednesday. The company has a market capitalization of $199.23 billion, a PE ratio of 30.82, a price-to-earnings-growth ratio of 1.83 and a beta of 0.75. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The business’s fifty day moving average is $117.94 and its 200 day moving average is $125.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.24 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s payout ratio is presently 67.74%.

Insider Buying and Selling

In related news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.